AnaptysBio Inc ANAB:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/07/24 EDT
25.68UNCH (UNCH)
Volume
7,121
Close
25.68UNCH (UNCH)
Volume
313,648
52 week range
13.36 - 27.50
Loading...
  • Open25.97
  • Day High26.50
  • Day Low25.17
  • Prev Close25.68
  • 52 Week High27.50
  • 52 Week High Date02/26/24
  • 52 Week Low13.36
  • 52 Week Low Date11/28/23

Key Stats

  • Market Cap701.543M
  • Shares Out27.32M
  • 10 Day Average Volume0.53M
  • Dividend-
  • Dividend Yield-
  • Beta-0.32
  • YTD % Change19.89

KEY STATS

  • Open25.97
  • Day High26.50
  • Day Low25.17
  • Prev Close25.68
  • 52 Week High27.50
  • 52 Week High Date02/26/24
  • 52 Week Low13.36
  • 52 Week Low Date11/28/23
  • Market Cap701.543M
  • Shares Out27.32M
  • 10 Day Average Volume0.53M
  • Dividend-
  • Dividend Yield-
  • Beta-0.32
  • YTD % Change19.89

RATIOS/PROFITABILITY

  • EPS (TTM)-6.07
  • P/E (TTM)-4.23
  • Fwd P/E (NTM)-4.10
  • EBITDA (TTM)-163.759M
  • ROE (TTM)-93.44%
  • Revenue (TTM)17.157M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-953.66%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/09/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On AnaptysBio Inc

Profile

MORE
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The...
John Orwin
Chairman of the Board
Daniel Faga
President, Chief Executive Officer, Director
Eric Loumeau J.D.
Chief Operating Officer, General Counsel
Dennis Mulroy CPA
Chief Financial Officer
Address
10770 WATERIDGE CIRCLE, SUITE 210
San Diego, CA
92121
United States

Top Peers

SYMBOLLASTCHG%CHG
AUTL
Autolus Therapeutics PLC
4.01UNCHUNCH
COGT
Cogent Biosciences Inc
7.76UNCHUNCH
IRON
Disc Medicine Inc
30.04UNCHUNCH
DNTH
Dianthus Therapeutics Inc
24.04UNCHUNCH
HLVX
Hillevax Inc
13.89UNCHUNCH